Equities

Aclarion Inc

ACON:NAQ

Aclarion Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.177
  • Today's Change-0.008 / -4.32%
  • Shares traded216.66k
  • 1 Year change-97.43%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS), and proprietary biomarkers to optimize clinical treatments. It has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that the Company has demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. It uses a magnet to apply a pulsed magnetic field to a patient, sensors to detect radio waves that emanate from the resonant vibrations of different chemicals in the body in response to that pulsed magnetic field and a computer to create detailed images of tissue structures in the patient based on those detected chemical signals.

  • Revenue in USD (TTM)53.95k
  • Net income in USD-5.90m
  • Incorporated2008
  • Employees6.00
  • Location
    Aclarion Inc8181 Arista Place, Ste 100BROOMFIELD 80021United StatesUSA
  • Phone+1 (650) 241-1740
  • Fax+1 (302) 636-5454
  • Websitehttps://aclarion.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
LadRx Corp0.00-2.77m1.23m2.00---------5.59-5.590.00-1.890.00----0.00-113.62-58.97-653.73-78.44--------------------106.96------
GRI Bio Inc0.00-8.28m1.29m4.00--0.0749-----100.69-100.690.005.880.00----0.00-130.64-192.93-187.01-353.99-------37,650.49----0.00-------85.61--29.46--
Emmaus Life Sciences Inc19.97m-5.26m1.34m51.00------0.0672-0.0824-0.08240.2506-0.89270.52390.52473.93391,529.40-13.79------95.48---26.32--0.1153-0.1451----60.94--64.87------
Regen BioPharma Inc236.57k-882.60k1.35m1.00------5.72-0.2157-0.21570.0594-1.181.04--3.82236,570.00-407.33-104.36---------392.01-275.00---1.36----0.441618.79-58.11------
Aditxt Inc329.75k-43.31m1.38m47.00--0.1162--4.18-77.20-77.200.3033.290.01850.60820.83937,015.96-242.33-192.78-1,548.63-321.59-46.09---13,105.77-7,208.650.0458-3.530.5084---30.90---18.11------
Seelos Therapeutics Inc2.01m4.09m1.40m8.000.0205----0.69419.769.761.43-8.470.2823--6.51134,266.7057.34-180.05---386.76----203.13-9,612.88---608.33--------48.48------
Aclarion Inc53.95k-5.90m1.60m6.00--0.885--29.64-4.74-4.740.01460.200.0212--3.598,991.67-231.70---714.18---51.53---10,937.05-----111.150.3212--24.75--34.38------
Panbela Therapeutics Inc0.00-28.56m1.65m7.00---------84.64-84.640.00-2.180.00----0.00-197.23-215.89-3,522.07-476.38-----------143.57--------27.68------
Hi-Great Group Holding Co71.99k-74.35k1.78m--------24.73-0.0007-0.00070.0007-0.00130.71490.627-----73.83------51.28---103.28--0.0099-20.74-----47.32---3,789.70------
Axim Biotechnologies Inc92.90k-4.14m1.81m6.00------19.50-0.0163-0.01630.0003-0.03240.0233----15,483.33-103.73-154.34---390.7316.94---4,451.97-36,362.71---3.14----345.05-27.38-29.10------
Pharmagreen Biotech Inc1.56k-500.66k1.92m0.00------1,233.70-0.0011-0.00110.00-0.00450.0094--3.35---302.10-472.20----11.54---32,096.15--0.0194-71.71--------80.68------
Cyclacel Pharmaceuticals Inc80.00k-17.61m1.93m12.00--1.77--24.18-16.14-16.140.04230.55340.0065--0.0547---142.14-57.58-327.21-69.81-----21,882.50-18,789.29---100.520.00----22.87-6.34---31.23--
Novelstem International Corp18.00k-1.65m1.97m15.00------109.39-0.0352-0.03520.0004-0.05410.0081--8.00---63.77-----------7,867.33-----2.132.61--0.00---446.84------
Data as of Sep 20 2024. Currency figures normalised to Aclarion Inc's reporting currency: US Dollar USD

Institutional shareholders

3.64%Per cent of shares held by top holders
HolderShares% Held
CapFinancial Partners LLCas of 30 Jun 2024164.03k1.82%
Geode Capital Management LLCas of 30 Jun 202442.06k0.47%
UBS Securities LLCas of 30 Jun 202439.92k0.44%
Two Sigma Securities LLCas of 30 Jun 202432.10k0.36%
Citadel Securities LLCas of 30 Jun 202428.84k0.32%
Ground Swell Capital LLCas of 30 Jun 202412.95k0.14%
Tower Research Capital LLCas of 30 Jun 20249.21k0.10%
BofA Securities, Inc.as of 30 Jun 2024100.000.00%
Bank of America, NA (Private Banking)as of 30 Jun 202467.000.00%
Beaird Harris Wealth Management LLCas of 30 Jun 202425.000.00%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.